NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.